## **Product Datasheet**

### Cytokeratin 17 Antibody (SPM560) [Alexa Fluor® 647] NBP2-34425AF647

Unit Size: 0.1 ml

Store at 4C in the dark.

www.novusbio.com

technical@novusbio.com

Protocols, Publications, Related Products, Reviews, Research Tools and Images at: www.novusbio.com/NBP2-34425AF647

Updated 10/23/2024 v.20.1

# Earn rewards for product reviews and publications.

Submit a publication at www.novusbio.com/publications Submit a review at www.novusbio.com/reviews/destination/NBP2-34425AF647



#### NBP2-34425AF647

Cytokeratin 17 Antibody (SPM560) [Alexa Fluor® 647]

Unit Size    0.1 ml      Concentration    Please see the vial label for concentration. If unlisted please contact technical services.      Storage    Store at 4C in the dark.      Clonality    Monoclonal      Clone    SPM560      Preservative    0.05% Sodium Azide      Isotype    IgG2b Kappa      Conjugate    Alexa Fluor 647      Purity    Protein A or G purified      Buffer    50mM Sodium Borate      Product Description    Mouse      Gene ID    3872      Gene Symbol    KRT17      Species    Human, Rat, Porcine, Bovine, Goat      Marker    Basal Epithelial Marker      Specificity/Sensitivity    Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate cells of complex epithelia but not in stratified or simple epithelial CK17 is expressed in the basal cells of complex epithelia but not in stratified or simple epithelial CK17 is a experimet tool to distinguish mycepithelial cells of various origins, such as bronchial epithelial cells of various origins, such as bronchial epithelial cells of various cell carcinomas (SCL0), especially for poorly-differentiated lung carcinoma. CK17 is expressed in splithelial cells and skin appendages. It may be considered as "epithelia them cell marker because CK17 Ab marks basal cell differentiation. CK17 can be useflut when included in a panel of antibodise aga		
Concentration    Please see the vial label for concentration. If unlisted please contact technical services.      Storage    Store at 4C in the dark.      Clonality    Monoclonal      Clone    SPM560      Preservative    0.05% Sodium Azide      Isotype    IgG2b Kappa      Conjugate    Alexa Fluor 647      Purity    Protein A or G purified      Buffer    50mK Sodium Borate      Product Description    Mouse      Gene 1D    3872      Gene Symbol    KRT17      Species    Human, Rat, Porcine, Bovine, Goat      Marker    Basal Epithelial Marker      Specificity/Sensitivity    Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in statified or simple epithelial CK17 is an explement tool to distinguish mycepithelial cells of various criggiss, such as bronchial epithelial cells and such as portages. It may be considered as tepithelial tore or algo signist TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation. ECK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and Umg signamous cell carcinoma (SCL0), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCL0 much higher	Product Information	
services.StorageStore at 4C in the dark.ClonalityMonoclonalCloneSPM560Preservative0.05% Sodium AzideIsotypeIgG2b KappaConjugateAlexa Fluor 647PurityProtein A or G purifiedBuffer50mM Sodium BorateProduct Description872HostMouseGene ID3872Gene SymbolKRT17SpeciesHuman, Rat, Porcine, Bovine, GoatMarkerBasal Epithelial MarkerSpecificity/SensitivityCytokaratin 17 (CN17) is a member of the Cytokaratin subfamily of intermediate appendages. Antibody to CN17 is an excellent to to to disinguish mycepithelial appendages. Antibody to CN17 is an appendages. It may be considered as repithelial epithelial but not in stratified or simple epithelial. CK17 is a expressed in the nail bed, hair follice, sebaceous glands and other epidermal appendages. Antibody to CK17 is an appendages. It may be considered as repithelial epithelial cells of various origins, such as bronchial epithelial cell marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation for bergitive filterentiation of the cytoker as in SCLC much hipiper than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER. PR and Her2, which are defined as triple negative breast carcinomas, approximately 20% of patient show no expression of ER. PR and Her2, which are defined as triple negative breast carcinomas, approximately 20% of patient show no expression of ER. PR and Her2, which are defined as triple negative breast carcinomas, approximately 20% of patient show no ex	Unit Size	0.1 ml
Clonality    Monoclonal      Clone    SPM560      Preservative    0.05% Sodium Azide      Isotype    IgG2b Kappa      Conjugate    Alexa Fluor 647      Purity    Protein A or G purified      Buffer    SomM Sodium Borate      Product Description    House      Gene ID    3872      Gene Symbol    KRT17      Species    Human, Rat, Porcine, Bovine, Goat      Marker    Basal Epithelial Marker      Specificity/Sensitivity    Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPS). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair folicide, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK171 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be conidered as 'epithelial cells or various origins, such as bronchial epithelial cells and skin appendages. It may be conidered as 'epithelial cells or various origins, such as bronchial epithelial cells and skin appendages. It may be conidered as 'epithelial cells or various origins, such as bronchial epithelial cells or various origins, such as bronchial epithelial cells and skin appendages. It may be corabidered as 'epithelial cell	Concentration	•
Clone    SPM560      Preservative    0.05% Sodium Azide      Isotype    IgG2b Kappa      Conjugate    Alexa Fluor 647      Purity    Protein A or G purified      Buffer    50mM Sodium Borate      Product Description    Horse      Host    Mouse      Gene ID    3872      Gene Symbol    KRT17      Species    Human, Rat, Porcine, Bovine, Goat      Marker    Basal Epithelial Marker      Specificity/Sensitivity    Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia CH17 is expressed in the basal cells of complex epithelia cells of various origins, such as bronchial epithelial cells of Various origins, such as bron	Storage	Store at 4C in the dark.
Preservative  0.05% Sodium Azide    Isotype  IgG2b Kappa    Conjugate  Alexa Fluor 647    Purity  Protein A or G purified    Buffer  50mM Sodium Borate    Product Description  Mouse    Gene ID  3872    Gene Symbol  KRT17    Species  Human, Rat, Porcine, Bovine, Goat    Marker  Basal Epithelial Marker    Specificity/Sensitivity  Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish mycopithelial cells from luminal epithelial cells of various origins, such as boronchial epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, pc63, and SOX-2 for diagnostic differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, pc63, and SOX-2 for diagnostic differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, pc63, and SOX-2 for diagnostic differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, pc63, and SOX-2 for diagnostic d	Clonality	Monoclonal
Isotype  IgG2b Kappa    Conjugate  Alexa Fluor 647    Purity  Protein A or G purified    Buffer  50mM Sodium Borate    Product Description  Mouse    Gene ID  3872    Gene Symbol  KRT17    Species  Human, Rat, Porcine, Bovine, Goat    Marker  Basal Epithelial Marker    Specificity/Sensitivity  Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as marmary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial epithelial cells of various cell carcinoma (SCLC), especially for poorty-differentiated lung carcinoma. CK17 ka baraks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five presents on fOLC. The seast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of xmputary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.	Clone	SPM560
Conjugate  Alexa Fluor 647    Purity  Protein A or G purified    Buffer  50mM Sodium Borate    Product Description	Preservative	0.05% Sodium Azide
Purity    Protein A or G purified      Buffer    50mM Sodium Borate      Product Description       Host    Mouse      Gene ID    3872      Gene Symbol    KRT17      Species    Human, Rat, Porcine, Bovine, Goat      Marker    Basal Epithelial Marker      Specificity/Sensitivity    Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells of various orgins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial cells morel' marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are agressive clinical course. The histologic differentiation of amguessite clinical course. The histologic differentiation of amguessite clinical course. The histologic differentiation of amgulary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 and anti-CDX-2 positivity defines intestinal subtype.	Isotype	IgG2b Kappa
Buffer  50mM Sodium Borate    Product Description  Mouse    Gene ID  3872    Gene Symbol  KRT17    Species  Human, Rat, Porcine, Bovine, Goat    Marker  Basal Epithelial Marker    Specificity/Sensitivity  Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish mycepithelial cells from luminal epithelial cells of various origins, such as bronchial epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in appanel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarionma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 and anti-CDX-2 positivity defines intestinal subtype.	Conjugate	Alexa Fluor 647
Product Description      Host    Mouse      Gene ID    3872      Gene Symbol    KRT17      Species    Human, Rat, Porcine, Bovine, Goat      Marker    Basal Epithelial Marker      Specificity/Sensitivity    Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish mycepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and solivary. CK17 is expressed in appendages. It may be considered as 'epithelial esitem cell' marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SLCL much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usu	Purity	Protein A or G purified
HostMouseGene ID3872Gene SymbolKRT17SpeciesHuman, Rat, Porcine, Bovine, GoatMarkerBasal Epithelial MarkerSpecificity/SensitivityCytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelian cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial setm cell' marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti- MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.	Buffer	50mM Sodium Borate
Gene ID3872Gene SymbolKRT17SpeciesHuman, Rat, Porcine, Bovine, GoatMarkerBasal Epithelial MarkerSpecificity/SensitivityCytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squarous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinoma immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti- MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.	Product Description	
Gene Symbol  KRT17    Species  Human, Rat, Porcine, Bovine, Goat    Marker  Basal Epithelial Marker    Specificity/Sensitivity  Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelial cells of various glands such as marmary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.	Host	Mouse
SpeciesHuman, Rat, Porcine, Bovine, GoatMarkerBasal Epithelial MarkerSpecificity/SensitivityCytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti- MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.	Gene ID	3872
MarkerBasal Epithelial MarkerSpecificity/SensitivityCytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelian cells of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti- MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.	Gene Symbol	KRT17
Specificity/Sensitivity Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiate lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.	Species	Human, Rat, Porcine, Bovine, Goat
filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti- MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.	Marker	Basal Epithelial Marker
Immunogen The cytoskeletal fraction of rat colon epithelium	Specificity/Sensitivity	filament proteins (IFPs). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as 'epithelial stem cell' marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK56, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.
	Immunogen	The cytoskeletal fraction of rat colon epithelium



	5 1
Notes	Alexa Fluor (R) products are provided under an intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: (i) in manufacturing; (ii) to provide a service, information, or data in return for payment; (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
Product Application Details	
Applications	Western Blot, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, CyTOF-ready
Recommended Dilutions	Western Blot, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry-Paraffin, CyTOF-ready





#### Novus Biologicals USA

10730 E. Briarwood Avenue Centennial, CO 80112 USA Phone: 303.730.1950 Toll Free: 1.888.506.6887 Fax: 303.730.1966 nb-customerservice@bio-techne.com

#### **Bio-Techne Canada**

21 Canmotor Ave Toronto, ON M8Z 4E6 Canada Phone: 905.827.6400 Toll Free: 855.668.8722 Fax: 905.827.6402 canada.inquires@bio-techne.com

#### **Bio-Techne Ltd**

19 Barton Lane Abingdon Science Park Abingdon, OX14 3NB, United Kingdom Phone: (44) (0) 1235 529449 Free Phone: 0800 37 34 15 Fax: (44) (0) 1235 533420 info.EMEA@bio-techne.com

#### **General Contact Information**

www.novusbio.com Technical Support: nb-technical@biotechne.com Orders: nb-customerservice@bio-techne.com General: novus@novusbio.com

#### Products Related to NBP2-34425AF647

NBP1-43317AF647	Mouse IgG2b Kappa Light Chain Isotype Control (MG2b) [Alexa Fluor® 647]
NBP2-51594-0.1mg	Recombinant Human Cytokeratin 17 His Protein
H00003872-T01	Cytokeratin 17 293T Cell Transient Overexpression Lysate
MAB1417	Insulin Antibody (182410) [Unconjugated]

#### Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-34425AF647

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications

www.novusbio.com

